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ABSTRACT 
Protein interactions with other proteins or small molecules are critical to most 
physiological processes. These interactions may be characterized experimentally, but this 
can be time consuming and expensive; computational methods for predicting how two 
proteins interact, or which regions of a protein are most favorable for binding, are thus 
valuable tools for understanding how proteins of interest function, and have applications 
in drug discovery and identifying proteins of therapeutic interest. The ClusPro and 
FTMap algorithms for docking or solvent mapping, respectively, model protein-protein 
and protein-small molecule interactions, and can be used to identify the most likely 
orientations of a protein complex or the regions on a protein surface with the greatest 
propensity for binding. Here we describe three applications of ClusPro and FTMap. 
ClusPro was used to develop a method for determining whether a protein-protein 
interface is biologically relevant, by docking the proteins and comparing the results to the 
given interface; a larger number of near-native structures--which have interfaces similar 
to that of the given complex--was found to correspond to a greater probability that an 
interface is biological. In another project, ClusPro was used to predict whether a mutation 
in a multimeric complex would trigger the formation of a supramolecular assembly, 
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based on how often that mutated residue appeared in the interfaces of the docking results; 
if a mutation caused such a residue to be present in the docked interfaces more often, in 
comparison to those of the wild-type structure, then it was likely to induce self-assembly. 
FTMap was used to detect and analyze the druggability of potential allosteric sites in 
kinases, with mapping performed on all available kinase structures to identify and 
determine the potential binding affinity of binding hot spots located outside of the active 
site. Discrimination of proteins as dimers or monomers was implemented as an addition 
to the ClusPro server, ClusPro-DC, and the results of the druggability analysis of kinases 
were organized into an online resource, the Kinase Atlas. 
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CHAPTER ONE 
Introduction 
Proteins play key roles in most biological processes, and their interactions with 
other proteins or with smaller ligands are essential to carrying out these functions, which 
include signal transduction, membrane transport, and control of cell cycle progression. 
The binding of a ligand to a protein (either a small molecule or another protein) can 
induce conformational changes in the protein that alter its behavior, such as its activity 
level or its preferred binding partners; this property can be exploited to treat disorders 
that result from abnormal protein activity, as inhibitors (or activators) can be used to 
modulate the activity of a protein of interest. The ability to identify a protein’s binding 
partners or the regions on a protein where binding is likely to occur is thus crucial in drug 
discovery, in order to determine whether a protein is involved in a biological process of 
interest and should be targeted--and if so, to design a small molecule or protein that will 
bind to the protein and produce the desired effect.  
Determining whether two proteins interact with each other can be done 
experimentally (with methods such as yeast two-hybrid screening and affinity 
purification/mass spectrometry) or computationally, if the proteins’ structures are known. 
Computational prediction of protein-ligand interactions can be performed with 
conformational changes permitted (flexible docking) or not (rigid-body docking); 
proteins often undergo conformational changes upon binding, but accounting for 
flexibility is computationally expensive, so docking with the rigid-body assumption is 
often sufficient, especially if conformational changes are minor. The following section 
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describes an algorithm for rigid-body docking, PIPER, that generates docked 
conformations for use in both ClusPro, which predicts likely orientations for protein-
protein complexes, and FTMap, which identifies favorable regions for small molecule 
binding. 
 
1.1 Rigid-body Docking with PIPER 
PIPER is a rigid-body docking algorithm that samples billions of docked 
conformations, using Fast Fourier Transforms (FFT) to evaluate the approximate energies 
of the potential complexes in an efficient manner (Kozakov et al., 2006). Conformations 
are generated by holding one structure fixed (the receptor) while the second structure (the 
ligand) is moved and rotated around the receptor on the basis of translational and 
rotational grids. Protein-protein docking uses a 1 Å translational grid and 70,000 
rotations, whereas for small molecules, a 0.8 Å translational grid and 500 rotations are 
used.  
The energy function that describes these receptor-ligand interactions can be 
expressed as the sum of P correlation functions for all possible translations α, β, γ of the 
ligand for a specific rotation: 
 
where Rp(i,j,k) and Lp(i,j,k) are the components of the correlation function defined on the 
receptor and the ligand, respectively. This expression can be efficiently calculated using 
P forward and one inverse Fast Fourier transform, denoted by FT and IFT, respectively:  
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where i = −1, N1, N2, and N3 are the dimensions of the grid along the three coordinates. 
If N1 = N2 = N3 = N, then the FFT approach results in an efficiency of O(N3 log(N3)), 
rather than O(N6) if all evaluations were performed directly (Cooley and Tukey, 1965).  
 
1.1.1 Scoring Function 
The energy function is composed of terms that represent shape complementarity, 
electrostatic, and desolvation contributions, with desolvation described by a pairwise 
potential: 
 
where NR and NL are the numbers of atoms in the receptor and ligand, respectively. The 
shape complementarity term in these expressions, Eshape, includes both attractive and 
repulsive interactions; the repulsive component is intended to prevent atomic overlaps. 
The electrostatic term Eelec is given by a simplified generalized Born-type expression. 
The coefficients w1, w2, and w3 are used to give different weights to each contribution in 
the scoring function; w1 is chosen to prevent major steric clashes while allowing some 
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atomic overlaps to occur, in order to account for minor differences between the structures 
of proteins crystallized individually from those crystallized as a complex. These 
conformational changes are assumed to be moderate, but if significant changes in the 
backbone structure occur, then PIPER is unlikely to perform well, as it does not account 
for backbone flexibility. The other two coefficients, w2, and w3, may be adjusted 
depending on the type of proteins being docked (such as enzyme-inhibitor or antibody-
antigen complexes) in order to optimize performance.  
 
1.1.2 DARS 
PIPER uses the pairwise structure-based potential DARS (Decoys As the 
Reference State) to represent desolvation contributions to the interaction energy (Chuang 
et al., 2008). The statistical potential between two atoms of types I and J, respectively, 
can be expressed as: 
 
where R is the gas constant, T is the temperature, and pIJ is the probability that two atoms 
of types I and J will interact. This probability can be approximated by 
 
where for atom types I and J, νobsIJ is the observed number of interacting pairs, and νrefIJ is 
the expected number of interacting pairs in a reference state. A relatively unbiased 
reference set for use in DARS was generated by docking native protein-protein 
complexes using only shape complementarity for scoring; this resulted in “decoy” 
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complexes that resemble actual protein-protein complexes, but do not depend on specific 
atomic interactions.  
 
1.2 Protein-Protein Docking with ClusPro 
ClusPro is a web-based protein-protein docking server that uses PIPER to perform 
rigid-body docking. The 1,000 lowest energy structures generated by PIPER are clustered 
by pairwise interface root-mean-square deviation (IRMSD) to find the largest clusters. 
An IRMSD radius of 9 Å is used for identifying which docked structure has the highest 
number of neighboring structures; this structure and all of its neighbors become the first 
cluster, and are removed from consideration, and the process then is repeated for the 
remaining structures until all structures have been assigned to a cluster. The clusters are 
then minimized using the van der Waals term of the CHARMM potential in order to 
remove remove steric overlaps. Finally, the centers of the 10 clusters with the largest 
populations are output as the results, with the position of the largest cluster considered to 
be the most likely orientation of the docked proteins. 
 
1.3 Computational Solvent Mapping with FTMap 
FTMap, a server for computational solvent mapping, identifies the most favorable 
regions on a protein for small molecules to bind. Mapping is a computational analogue of 
experimental methods for detecting binding hot spots, such as multiple solvent crystal 
structures (MSCS), in which a protein crystal is soaked in a series of organic solvents, 
and the structure of the soaked crystal is solved using X-ray crystallography in order to 
  
 
6 
determine where solvent molecules bind to the protein (Mattos and Ringe, 2006). Hot 
spots are regions within a binding pocket that contribute disproportionately to the binding 
free energy (Hadjuk et al., 2005), and in MSCS they also bind a large number and variety 
of solvent molecules. 
The FTMap algorithm follows a similar approach: sixteen small organic 
molecules are used as probes, and for a given protein structure, energetically favorable 
positions for these probes to bind are identified using PIPER (which, in comparison to 
docking, contains an additional term in the scoring function to favor binding in cavities). 
For each probe, the 2,000 lowest energy poses are retained and their orientations are 
refined using the CHARMM potential with analytical continuum electrostatics (ACE) 
model (Brooks et al., 1983; Schaefer and Karplus, 1996), which accounts for 
electrostatics and solvation; the probe molecules are then clustered using a 4 Å radius, 
beginning with the lowest energy probe, and the probe clusters are ranked using their 
Boltzmann average energies. The six lowest energy probe clusters for each probe are 
retained, and then clusters for every type of probe molecule are clustered together, again 
using a 4 Å radius, in order to form the consensus sites. Consensus sites identify the 
locations of binding hot spots on the protein surface, and their rank, which is based on 
their population of probe clusters, corresponds to the relative strength and importance of 
the associated hot spot.  
 
1.4 Contributions 
Bing Xia created the website for the Kinase Atlas (Chapter 2) and began the work 
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of implementing ClusPro-DC as a server (Chapter 3). David Hall performed some of the 
kinase mappings for Chapter 2, wrote the program used in Chapter 4 to count how often 
specific residues appeared in docked interfaces, and worked with me to finish the 
ClusPro-DC server (Chapter 3).  
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CHAPTER TWO 
Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases 
2.1 Introduction 
Members of the protein kinase family play vital roles in cellular physiology and  
are major drug targets (Roskoski, 2016), as they have been implicated in many types of 
diseases such as cancer, diabetes, neurodegeneration, and inflammation. Their association 
with a wide variety of ailments stems from their involvement in nearly all cellular 
processes, since they are responsible for regulating the activity of other proteins 
(Manning et al., 2002).  
 
Figure 2.1: Structure of the kinase catalytic domain. ATP is shown in yellow, the N-
terminus in green, and the C-terminus in gray. 
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Currently, 37 small molecules have been approved by the FDA as kinase 
inhibitors, and the vast majority of these target the active site, which is located between 
the N- and C-terminal domains and binds ATP (Bajusz et al., 2017). Inhibitors that bind 
to the ATP pocket in the active form of the kinase are known as “type I” kinase inhibitors 
(Roskoski, 2016), and despite their popularity, the development process presents two 
major challenges: first, type I inhibitors must bind with enough potency to overcome high 
physiological concentrations of ATP, and second, the ATP site is highly conserved 
between all kinases, making it difficult to design inhibitors with enough selectivity to 
bind only to their intended targets (Fang et al., 2013). Alternatively, kinase inhibitors can 
be classified as “type II” if they target the ATP site but bind to an inactive conformation 
known as “DFG-out”, in which a conserved DFG (Asp-Phe-Gly) motif partially blocks 
the ATP pocket (Roskoski, 2016). Type II inhibitors, which make up about a quarter of 
approved kinase inhibitors, often extend into the hydrophobic back pocket formed in the 
“DFG-out” state, and as this pocket is far less conserved than the active site, binding here 
offers the potential to achieve sufficient selectivity more easily (Vijayan et al., 2015). 
Allosteric kinase inhibitors, which do not target the ATP site at all, are classified by 
where they bind: type III bind to the active kinase conformation in a pocket adjacent to 
the ATP site, whereas type IV bind away from ATP site entirely (Roskoski, 2016). 
Although type III and IV inhibitors would potentially face fewer issues with potency 
and/or selectivity than ATP-competitive inhibitors, they remain far less common: only 
two of the FDA-approved kinase inhibitors (trametinib and cobimetinib) would be 
considered type III (Roskoski, 2017), and no inhibitors that bind to the kinase catalytic 
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domain would be considered type IV (Roskoski, 2016).  
 
 
Figure 2.2: Difference between active “DFG-in” and inactive “DFG-out” conformations. 
ATP is shown in yellow, “DFG-in” conformation in pink, “DFG-out” conformation in 
blue, and the “DFG-out” pocket in orange. In the inactive “DFG-out” conformation, the 
Phe residue of the DFG motif moves to partially block the ATP site, preventing ATP 
binding and exposing the “DFG-out” pocket. 
 
Here we have explored the potential of kinase allosteric sites as targets for 
inhibition, since they have been relatively underutilized for kinase drug development. To 
detect and assess the druggable potential of these sites, we used FTMap, a computational 
analogue of experimental fragment screening (Kozakov et al., 2015a), to identify binding 
hot spots on all available kinase structures in the Protein Data Bank (Berman et al., 
2000). Hot spots are small regions within a binding site that contribute disproportionately 
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to the binding free energy, and they can be detected in a protein structure even without 
ligand binding information or an obvious pocket, since they tend to bind a large number 
and variety of small molecules even in an unliganded state. FTMap finds consensus sites, 
which are regions on the protein surface that bind a large number of small molecule 
probe clusters; thus, we can use FTMap to identify binding hot spots even in unliganded 
structures, as well as to estimate the potency with which they could bind potential 
ligands, since consensus site size corresponds to potential binding affinity (Kozakov et 
al., 2015b).  
In addition to the pockets associated with type II and III inhibitors, we have 
identified ten sites on the kinase catalytic domain that have been described in the 
literature as being involved in either regulating the activity of a kinase, or the ability of a 
kinase to regulate the activity of its substrates. Seven of these sites are known to bind 
compounds that exhibit IC50 values in the micromolar or even nanomolar range, whereas 
the other three should be considered more speculative. Since the structure of the kinase 
catalytic domain is fairly conserved (Fang et al., 2013), an allosteric site found on one 
kinase may be present in the same location on other kinases, although the structures and 
sequences of these analogous pockets would differ between kinases--unlike the ATP site, 
which is relatively similar between all kinases. This is already known to be true of the 
DFG-out pocket, for example, which is found in many different kinases (Vijayan et al., 
2015), and many of the other potential allosteric sites we have identified are also 
associated with more than one kinase. 
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Figure 2.3: Positions of all allosteric sites discussed in this paper; ATP is represented as 
yellow sticks, the N-terminal domain is shown in green, and the the C-terminal domain is 
shown in gray. From top to bottom: MPP (cyan), PIF (purple), MT3 (orange), DFG (red), 
DRS (blue), PMP (pink), PDIG (dark green), AAS (light yellow), CMP (brown), DEF 
(teal), LBP (magenta), EDI (olive).   
 
Our FTMap results for all kinase structures have been made available online as 
the Kinase Atlas (https://kinase-atlas.bu.edu), intended as a resource for researchers 
interested in kinases. Users may view summarized results for all structures of a particular 
kinase, such as which allosteric sites are present on the kinase and how druggable they 
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are, or they may view or download FTMap results for a particular kinase structure of 
interest. The Kinase Atlas can thus be used either to discover where to target a kinase of 
interest, or whether a kinase is worth targeting at all, as some kinases do not have any 
structures with strong enough consensus sites to be considered druggable. In comparison 
to the active site, allosteric sites are rarely considered as targets for inhibitor 
development, but the Kinase Atlas shows that many of these pockets have the potential to 
be druggable, and may be worth pursuing.  
 
2.2 Results 
The Kinase Atlas contains FTMap results for 3887 unique PDB IDs, 
corresponding to 4910 total kinase structures from 376 different kinases, and assigns 
consensus sites to 12 different potential allosteric sites. Each allosteric site has a “source” 
kinase that it is known to be found in--or in the case of sites that are found in multiple 
kinases, the kinase with which it is most widely associated--and FTMap was able to 
identify hot spots located at each site in an unliganded structure of the “source” kinase for 
all sites. Not every binding site with druggable potential will have a liganded structure or 
binding data available, so being able to detect binding hot spots in unliganded structures 
is often useful in determining whether a protein is likely to be druggable as well as which 
regions to target (Kozakov et al., 2015b).  
Each allosteric site and its FTMap results are described briefly in Table 2.1, and 
in more detail in the following sections. Most of them were found to be druggable in at 
least one unliganded structure; the structure with the strongest consensus site(s) for each 
  
 
14 
allosteric site is listed in Table 2.2 and shown in Figure 2.4. The number of kinases that 
were found to be druggable at each allosteric site varied widely, with some sites being 
found in as few as 6 kinases, and others in well over 100 kinases, as seen in Table 2.3; 
ATP is not an allosteric site, but it is included as a reference. An allosteric site being 
“common” does not necessarily render it unsuitable as a target, however, as allosteric 
sites are not as conserved as the ATP site is between different kinases.  
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Table 2.1: Descriptions of each pocket 
Site Site Name Origin 
Inhibitor 
Type Pocket Description 
DFG DFG motif II 
Hydrophobic pocket that opens up when DFG 
motif switches to inactive "DFG-out" 
conformation; binding here may stabilize inactive 
kinase conformation 
MT3 MEK1/2 type III inhibitor III 
Adjacent to ATP and DFG-out pockets; binding 
disrupts salt bridge required for kinase activity 
PIF 
PDK1 
interacting 
fragment 
IV PDK1 regulates other AGC kinases by recruiting them through this site 
MPP MKK4 p38a peptide IV 
p38a peptide binding inhibits MKK4 by inducing 
conformational changes that lead to auto-inhibition 
CMP 
c-Abl 
myristoyl 
pocket 
IV 
Ligand binding here can lead to an active (small 
ligand) or inactive (bulky ligand) state in c-Abl by 
affecting SH domain binding 
PMP 
PKA 
myristoyl 
pocket 
IV Myristoyl binding at this site activates membrane binding in PKA 
DRS D-recruitment site IV Substrate docking site present in all MAP kinases 
DEF docking site for ERK FXF IV 
Substrate docking site present in some MAP 
kinases; located near MAPK insert 
LBP lipid binding pocket IV 
Binding of different lipids here affects p38a 
MAPK's preference and activity for different 
substrates 
PDIG PDIG motif IV Substrate recognition site located near PDIG motif in Chk1 
AAS 
Aurora A 
activation 
segment 
IV An Aurora A monomer activates another through binding of its activation segment to this site 
EDI 
EGFR 
dimerization 
interface 
IV An EGFR monomer activates another by binding at this interface on the C-terminal domain 
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Table 2.2: Mapping results for each pocket 
Site Source Kinase 
Example 
PDB Ligand 
Binding 
Data 
Mapped 
Kinase 
Mapped 
PDB 
Consensus 
Sites 
DFG many 1iep imatinib IC50 = 10.8 nM TIE2 1fvr_B 01(16) 
MT3 MEK1/2 4an2 cobimetinib IC50 = 0.9 nM MEK1 3eqf_A 00(20) 
PIF PDK1 4rqk RS1 Kd = 1.5 µM PDK1 3iop_A 
00(21) 
08(3) 
MPP MKK4 3alo p38a peptide n/a MKK4 3aln_A* 
01(20) 
03(11) 
CMP c-Abl 3k5v GNF-2 IC50 = 267 nM c-Abl 3qrj_B 
03(12) 
08(2) 
PMP PKA 1cmk myristoyl n/a PKA 4ae9_A 01(24) 04(08) 
DRS all MAPK's 1uki pepJIP1 
Kd = 0.42 
µM JNK3 4z9l_A 02(13) 
DEF some MAPK's 3o2m A-82118 
IC50 = 7.7 
µM JNK1 3v3v_A 
00(22) 
01(14) 
LBP p38a MAPK 3new 
compound 
10 
IC50 = 1.2 
µM 
p38a 
MAPK 3s4q_A 
00(21) 
03(15) 
PDIG Chk1 3jvs compound 3 Ki = 146 nM Chk1 4rvk_A 
00(17) 
09(1) 
AAS Aurora A 4c3p Aurora A 
Kd > 300 
µM 
Aurora 
A 3o51_A 
00(22) 
01(17) 
EDI EGFR 2rfe Mig6 Kd = 13 µM EGFR 4rj5_A 01(16) 
*Structure is liganded; no unliganded structures are available for this kinase 
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Table 2.3: Druggability results for each pocket 
 All Kinases (376) Human Kinases (239) 
Site Total Druggable Total Druggable 
AAS 234 128 158 86 
ATP 373 298 238 193 
CMP 200 76 145 61 
DEF 65 18 48 16 
DFG 272 93 190 71 
DRS 231 103 151 70 
EDI 232 109 148 69 
LBP 92 22 69 16 
MPP 249 138 171 102 
MT3 304 182 200 125 
PDIG 252 114 166 80 
PIF 199 116 141 87 
PMP 21 6 13 2 
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Figure 2.4: Mapping results for unliganded structures (except MPP) of kinases 
associated with each allosteric site, with superimposed ligands from bound structures 
shown as yellow sticks. Structure, ligand, and mapping details for each site are given in 
Table 2.2. 
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2.2.1 Sites with known inhibitors 
 
2.2.1.1 DFG (DFG-out pocket) 
The DFG-out pocket is a hydrophobic pocket that opens up when the conserved 
DFG motif changes conformation as a kinase switches from an active to an inactive state. 
In the active, DFG-in state, this site is occupied by the Phe residue in the DFG motif, and 
ATP can bind to the active site; in the inactive, DFG-out state, however, Phe instead 
partially occupies the ATP site, preventing ATP from binding and exposing the less 
conserved DFG-out pocket (Bajusz et al., 2017). Type II inhibitors, which bind to the 
DFG-out conformation, are ATP-competitive, but they frequently extend into the DFG-
out pocket (Roskoski, 2016); as this site differs more between kinases than the ATP site, 
binding here may allow inhibitors to be more selective, although existing type II 
inhibitors have not been found to be necessarily more selective than type I inhibitors 
(Zhao et al., 2014). FTMap results for known targets of type II inhibitors suggest that the 
DFG-out pocket may not be particularly strong; many structures were shown to be only 
borderline druggable at this site, although some kinases had apo structures with strong 
enough consensus sites for this site to be considered druggable. The ability of type II 
inhibitors to bind with nanomolar affinity (for example, imatinib exhibits an IC50 value of 
10.8 nM for c-Abl) (Dietrich et al., 2010) may be due mostly to the ATP pocket, with the 
DFG-out pocket playing a supporting role. 
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2.2.1.2 MT3 (MEK1/2 Type III inhibitor site) 
This site is based on where type III kinase inhibitors bind; it is located adjacent to 
the ATP and DFG-out sites, between the N- and C-terminal domains, and binding to this 
pocket disrupts a salt bridge required for kinase activity (Bajusz et al., 2017). Unlike the 
DFG-out pocket, this site is present in the active form of the kinase, and ligands can bind 
here even if the kinase is already bound to ATP (Roskoski, 2016).  FDA-approved type 
III inhibitors include trametinib and cobimetinib, both of which target MAPK/ERK 
kinase (MEK1/2) and have been used to treat melanoma (Roskoski, 2017). Mapping 
results show that this site is highly druggable, with strong consensus sites present even in 
unliganded structures of MEK1/2, which is consistent with experiments showing that 
type III inhibitors can be highly potent (IC50 = 0.9 nM for cobimetinib/MEK1) (Rice et 
al., 2012). An analogous pocket appears to be present in EGFR, which binds the inhibitor 
EAI045 with IC50 values as low as 3 nM (Jia et al., 2016). In comparison to the DFG-out 
site, this pocket appears to be druggable in a much higher number of kinases, but this 
may be partially due to DFG-in structures being much more common than DFG-out 
(Bajusz et al., 2017). 
 
2.2.1.3 PIF (PDK1 Interacting Fragment) 
The PIF pocket is a hydrophobic groove found on the N-terminal domain of 
phosphoinositide-dependent kinase 1 (PDK1), which uses this pocket to recruit the C-
terminal hydrophobic motif (HM) on other members of the AGC kinase family and 
thereby regulate their activity through phosphorylation (Hindie et al., 2009). PDK1 
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activity could thus be modulated through inhibitor binding at this site, as this would 
disrupt its interactions with its substrates and prevent PDK1 from either activating or 
inhibiting other kinases. Both activators (Hindie et al., 2009) and inhibitors (Bobkova et 
al., 2011; Rettenmaier et al., 2014) have been developed for the PIF pocket, with many in 
the low micromolar affinity range (as low as Kd = 1.5 µM for compounds developed by 
Rettenmaier et al.); these compounds could likely be optimized for even stronger binding, 
as mapping results indicate that this site is likely to be capable of binding compounds 
with nanomolar affinity. Mapping showed that this was also true for other AGC kinases, 
many of which are known to possess a similar pocket.    
 
2.2.1.4 CMP (c-Abl Myristoyl Pocket) 
The myristoyl pocket in Abelson tyrosine-protein kinase 1 (c-Abl) binds the 
myristoyl group from the N-terminal cap of the kinase, allowing SH3 and SH2 domains 
to associate and induce an autoinhibited state. This N-terminal cap is not present, 
however, in the fusion BCR-Abl oncogene, which results from a chromosomal 
translocation that fuses the breakpoint cluster region (BCR) with c-Abl; BCR-Abl thus 
cannot be autoinhibited by myristoylation, and its elevated activity leads to disorders 
such as chronic myelogenous leukemia (CML) (Nagar et al., 2003). CML can been 
treated with imatinib and other ATP-competitive inhibitors, but mutations near the ATP 
pocket in BCR-Abl are common and frequently lead to drug resistance (Woessner et al., 
2011). As the myristoyl pocket is located in the C-terminal domain, far from the ATP 
site, these mutations would be less likely to affect binding there. GNF-2 has been found 
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to bind at the myristoyl pocket in BCR-Abl, and similarly to the myristoyl group, it 
encourages SH2 and SH3 domain binding; it also induces conformational changes that 
promote binding of ATP-competitive inhibitors (Zhang et al., 2010). Alternatively, c-Abl 
can be activated by the binding of bulkier groups to the myristoyl pocket, such as DPH, 
which leads to conformational changes that prevent SH domains from associating with 
and inhibiting the kinase (Yang et al., 2011). FTMap results for c-Abl kinase structures 
showed that the myristoyl pocket is unlikely to be highly druggable (only a single, 
liganded structure was found to have a strong consensus site), which is consistent with its 
reported affinity (IC50 = 267 nM, or borderline druggable), and it appears that studies of 
whether GNF-2 inhibits BCR-Abl have used it in combination with an ATP-competitive 
inhibitor (Zhang et al., 2010; Khateb et al., 2012); this indicates that GNF-2 and other 
myristoyl pocket inhibitors may not be effective inhibitors of c-Abl if used alone. 
 
2.2.1.5 DRS (D-Recruitment Site) 
The D-recruitment site is found in the C-terminal domain of all mitogen-activated 
protein (MAP) kinases, a family that includes extracellular signal-regulated kinases 
(ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPKs. Its name comes from the 
“D-motif” sequences found in MAPK binders, and it contains two subsites to which D-
motifs bind, an acidic patch and a hydrophobic pocket (Akella et al., 2008). MAP kinases 
control intracellular responses to extracellular stimuli, phosphorylating their substrates 
within the cell after being activated by their upstream regulators, MAPK kinases (MKKs) 
(Johnson and Lapadat, 2002). Their interactions with other proteins in the MAPK signal 
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transduction pathway are thus critical to the regulatory role MAPKs play in most cellular 
processes, and the D-recruitment site is a major docking site for these interactions.  
Inhibitors have been developed to target the D-recruitment site, including peptides 
such as pepJIP1 (Heo et al., 2004) and small molecules such as BI-78D3 (Stebbins et al., 
2008); these inhibitors are mimetics of JIP1, a scaffold protein that enhances signaling in 
JNK, and compete with JIP1 to inhibit JNK activity. A small molecule natural product, 
rooperol, has also been shown to inhibit p38a MAP kinase (Li et al., 2013). None of these 
bind with the low nanomolar affinity that would be required for an appropriate drug 
candidate, however, with BI-78D3 being the most potent (IC50 = 280 nM) (Stebbins et 
al., 2008). Mapping results for MAPK structures suggest that developing compounds 
with greater affinity may not be likely, as the D-recruitment site was shown to be 
borderline druggable at best at the hydrophobic pocket, and not druggable at all at the 
acidic patch. Stronger binders that bind at the D-recruitment site with nanomolar affinity 
(IC50 = 18 nM) have been reported, but these are long molecules that also extend into the 
ATP site, rather than targeting the D-recruitment site alone (Stebbins et al., 2011). The D-
recruitment site is thus not a promising pocket to be targeted on its own for MAP kinases, 
but this region was shown to be have the potential to bind compounds with high affinity 
in related kinases, such as members of the MKK family. 
 
2.2.1.6 DEF (Docking site for ERK FXF)  
The DEF site is found in the C-terminal domains of several members of the MAP 
kinase family, such as ERK1/2, p38a MAPK, and JNK1 (Tzarum et al., 2013; Liu et al., 
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2016). It is also known as the FXF site, since it binds to the FXF motif found on several 
MAPK substrates, and it is located near the MAP kinase insert, where it appears after 
phosphorylation activates and induces conformational changes in ERK (Lee at al., 2004). 
Compounds that bind to MAP kinases at the DEF site have been reported, such as biaryl 
tetrazoles identified by Comess et al that inhibit JNK1 activation by MKK7 (IC50 = 7.7 
µM) (Comess et al., 2011), and mapping results suggest that the DEF site has the 
potential to be highly druggable, unlike the other major MAPK docking site, the D-
recruitment site. 
 
2.2.1.7 LBP (Lipid Binding Pocket) 
The lipid binding pocket is located in the C-terminal domain of p38a MAP 
kinases, near the MAP kinase insert. The biological relevance of this pocket has not been 
verified conclusively, but it appears to be able to accommodate a variety of lipids, and it 
has been suggested that binding different lipids may affect p38a MAPK’s catalytic 
activity and preference for specific substrates, particularly in cellular processes that 
involve lipids (Diskin et al., 2008). Several lipid-based molecules have been found to 
activate p38a MAPK upon binding to this site--such as phosphatidylinositol ether lipid 
analogues (PIAs) and perifosine, a phase II AKT/PKB inhibitor structurally similar to 
PIAs--by inducing conformational changes that lead to autophosphorylation (Tzarum et 
al., 2012). These lipids bind with low micromolar affinity to p38a MAPK (IC50 = 1.2 
µM), but mapping results indicate that this site would likely be able to bind ligands with 
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nanomolar affinity, since many structures of p38a MAPK had strong consensus sites at 
the lipid binding pocket.  
 
2.2.1.8 PDIG (PDIG motif site) 
This pocket is located near the PDIG motif in the C-terminal domain of 
Checkpoint kinase 1 (Chk1), an important regulator in the DNA damage response 
pathway. It appears to act as a substrate recognition site, and so Chk1 activity could 
potentially be inhibited by compounds that target this site and compete with substrate 
binding (Vanderpool et al., 2009). Several inhibitors have been developed that bind to 
this site with low micromolar affinity (as low as Ki = 146 nM), such as 
thioquinazolinones (Converso et al., 2009), carbamates, and semicarbazides (Vanderpool 
et al., 2009), and mapping results for Chk1 structures suggest that the site has the 
potential to bind compounds with even greater affinity. A similar pocket appears to be 
present on PIM1 kinase, which was found to bind mitoxantrone, an FDA-approved 
chemotherapy drug that targets type II topoisomerase (Wan et al., 2013). Mitoxantrone 
binds to two locations on PIM1, the substrate binding site (analogous to the one on Chk1) 
and the ATP site, with nanomolar affinity; this is in agreement with mapped structures of 
PIM1, which have strong consensus sites in this pocket. 
 
2.2.1.9 EDI (EGFR Dimerization Interface)  
Members of the epidermal growth receptor family (EGFR) are activated upon 
formation of an asymmetric dimer between two EGFR kinases, in which the C-terminal 
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domain of one kinase interacts with the N-terminal domain of the second kinase. This 
dimerization is considered analogous to the interaction between cyclin and cyclin-
dependent kinase (CDK), which activates CDK, and the inactive forms of CDK and 
EGFR are considered to be similar to each other (Zhang et al., 2006). Binding at the 
EGFR dimerization interface could thus be used to inhibit EGFR activity, since it would 
interfere with the ability of an EGFR monomer to be activated by another monomer. A 
peptide derived from MIG6 was found to inhibit EGFR by binding at and blocking the 
dimerization interface, exhibiting a Kd value of 13 µM (Zhang et al., 2007). CDK2 
appears to possess a similar pocket, as D-luciferin was found to bind in the same location 
and inhibit CDK2 (although it binds in two locations, with the other being the ATP site, 
so its contribution is less clear) (Rothweiler et al., 2015). Mapping showed that this site 
appears to be druggable in both EGFR and CDK2, with strong consensus sites present in 
this pocket in structures of both kinases, although it appears to be stronger in CDK2.  
 
2.2.2 Sites without known inhibitors 
 
2.2.2.1 PMP (PKA Myristoyl Pocket) 
The myristoyl pocket in protein kinase A (PKA) is located in the C-terminal 
domain, in a different area from the c-Abl myristoyl pocket, and myristate binding here 
appears to activate membrane association with PKA (Gaffarogullari et al., 2011). This 
pocket has received less attention than the myristoyl pocket in c-Abl, and does not appear 
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to be targeted by any inhibitors, but based on the mapping results of PKA structures, the 
PKA myristoyl pocket appears to be highly druggable. 
 
2.2.2.2 AAS (Aurora A Activation Segment) 
This pocket is present in Aurora A kinases in the C-terminal domain, between the 
PDIG and DEF sites. Autophosphorylation of Aurora A occurs when the activation 
segment on one monomer binds to this region on a second monomer, activating the 
second monomer (Zorba et al., 2014). Inhibitors do not appear to have been developed 
for this site, but mapping indicates that it is likely to be highly druggable, with multiple 
strong consensus sites located there in many mapped structures of Aurora A.  
 
2.2.2.3 MPP (MKK4 p38 Peptide site) 
This site is located on the N-terminal domain of MAP kinase kinase 4 (MKK4), 
which phosphorylates and activates members of the MAP kinase family, such as JNKs 
and p38 kinases. A p38a peptide was found to inhibit MKK4 by binding at this site and 
inducing an auto-inhibition state (Matsumoto et al., 2010). Few structures of MKK4 are 
available, and none of them are unliganded at this site, but the available structures were 
found to have strong consensus sites there. 
 
  
  
 
28 
2.3 Discussion 
 
2.3.1 Existing kinase databases 
The Kinase Atlas is the first database to focus on allosteric sites in kinases and 
their ability to bind potential ligands. The most similar existing database would likely be 
KLIFS, a structural kinase-ligand interaction database that covers the region of the kinase 
between the N- and C-terminal domains--which would include the DFG-out and MT3 
sites--and provides detailed structural and ligand-binding information for all human and 
mouse kinase structures available in the PDB (Kooistra et al., 2016). KLIFS provides a 
consistent numbering scheme for kinase residues and descriptions of subpockets within 
the catalytic cleft, which makes it simpler to compare how known ligands bind to kinases 
and identify potential patterns in kinase-ligand interactions.  
The goal of the Kinase Atlas, on the other hand, is to identify which allosteric 
sites on each kinase might be suited for inhibitor development, even without ligand-
binding data for that site--which is likely to be the case for most kinases. As described 
earlier, existing FDA-approved kinase inhibitors are overwhelmingly ATP-competitive, 
but they are also disproportionate in which kinases and diseases they target--as of 2015, 
18 out of the 27 protein kinase inhibitors targeted Tyrosine kinases (which comprise only 
90 out of the 518 human kinases (Manning et al., 2002), and 26 out of 28 kinase 
inhibitors were intended to treat cancer, even though many other diseases are associated 
with kinases (Wu et al., 2015). Similarly, the amount of structural and bioactivity data 
available for different kinases is also uneven, with over a quarter of the kinase bioactivity 
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data from ChEMBL covering just 18 kinases, and the most popular 10 kinases accounting 
for over 40% of kinase structures (Bajusz et al., 2017). Thus, for the vast majority of 
kinases without much ligand-binding data available, the Kinase Atlas could be a valuable 
resource for determining which regions are likely to be druggable, since FTMap can 
detect binding sites even in unliganded structures.  
 
2.3.2 How to use the Kinase Atlas 
The Kinase Atlas is available at https://kinase-atlas.bu.edu and contains FTMap 
results for all kinase structures available in the PDB. Each structure has its own page, 
where users may access consensus site data (including whether consensus sites 
corresponded to any allosteric sites), or they may download or visualize mapping results 
for that structure; downloaded results are available as PyMOL session files containing the 
protein structure that was mapped and the resulting consensus sites, which indicate the 
regions on the surface that would be most likely to bind ligands. For users interested in a 
particular kinase, summarized mapping results for the structures associated with each 
kinase (based on their UniProt accessions) are also available, listing the strongest (if any) 
consensus sites associated with each allosteric site on each structure. 
As an example, the serine/threonine kinase PKR (protein kinase R) has been 
linked to breast cancer (Kim et al., 2000), hepatocellular carcinoma (Delhem et al., 
2001), and Huntington’s disease (Peel et al., 2001), but it has just 3 structures of the full 
catalytic domain in the (PDB ID: 2a19, 2a1a, 3uiu) and 271 bioactivities listed in 
ChEMBL (many other kinases have thousands of associated bioactivities). FTMap found 
  
 
30 
that the AAS and PDIG sites were likely to be druggable in PKR, with both of them 
having strong consensus sites; several smaller consensus sites were also located near 
these pockets, fulfilling the criteria described by Kozakov et al. for being druggable by 
traditional druglike compounds (Kozakov et al., 2015b).  
 
Figure 2.5: FTMap results for apo PKR structure 3uiu_B, with superimposed inhibitor 
(compound 3) from Chk1 structure 3jvs (shown in yellow). The main hot spot is 
indicated by consensus site 01(18) (in magenta), with secondary consensus sites 07(5) (in 
light green) and 08(4) (in teal) indicating more minor hot spots.  Both secondary 
consensus sites have center-to-center distances from the main consensus site that are less 
than 8 Å, and the maximum dimension is greater than 10 Å; these results indicate that this 
site is likely to be druggable by a traditional small molecule drug (Kozakov et al., 2015b). 
 
2.3.3 Selection and naming of allosteric sites 
The two most well-known kinase allosteric sites would be the DFG-out and MT3 
pockets, both of which have FDA-approved inhibitors, and a literature search turned up 
descriptions of six other sites (PIF, CMP, DRS, PDIG, DEF, LBP). The remaining four 
sites (EDI, MPP, PMP, AAS) were identified after mapping was performed on all kinase 
structures, and several regions were frequently found to have strong consensus sites that 
were not associated with any of the previously identified allosteric sites. Kinases that 
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were found to have these hot spots then had their structures aligned with all other kinase 
structures to identify those that had either a protein-protein interaction site or a bound 
ligand/peptide in the same location as the consensus sites, and some of these structures 
were associated with publications that described an allosteric site in the regions of 
interest. Some kinase allosteric sites have established names; these tend to be based on 
either the “source” kinase (PIF, DEF), a motif located near the site (DFG), or a 
ligand/peptide that binds to the site (DRS, DEF). The remaining eight sites were thus 
named similarly, with all of them referencing the “source” kinase and ligand aside from 
PDIG (based on a motif) and LBP (based on the ligand only).  
 
2.4 Methods 
 
2.4.1 Kinase structure selection 
To obtain a list of kinase catalytic domain structures available for mapping, two 
resources were used: Pfam (Finn et al., 2016), a database for protein families, which 
groups proteins by sequence and matches them to PDB structures through UniProt (The 
UniProt Consortium, 2017), and the Gene Ontology (GO) project (The Gene Ontology 
Consortium, 2017), which describes gene products by their biological processes, 
molecular functions, and cellular components. A structure had to be classified as a 
“protein kinase domain” (Pkinase) by Pfam and having “protein kinase activity” as a 
molecular function by GO to be included for mapping. The final list contained over 4900 
  
 
32 
total kinase structures (from 3800 unique PDB IDs), which corresponded to 376 different 
kinases; 239 of these were human kinases. 
 
2.4.2 Mapping preparation 
After each kinase structure was downloaded from the Protein Data Bank (Berman 
et al., 2000), it was split into its N- and C-terminal domains before mapping. The active 
site in kinases is located between the domains and binds with high affinity to ATP, so 
separating the domains before mapping is required to break up the ATP site and allow 
potential allosteric sites to be detected. CATH, a database that classifies protein domains 
by secondary structure, was used to identify the domains in each structure (Dawson et al., 
2017). For structures without an entry in CATH, the classification from a similar 
structure (identified using BLAST) was applied.  
 
2.4.3 Assignment of mapping results to allosteric sites 
Each allosteric site was assigned a representative structure from the kinase of 
origin with a ligand (small molecule/inhibitor or peptide) known to bind at the allosteric 
site. After using PyMOL to align each representative structure to each mapped structure, 
consensus sites were assigned to allosteric sites based on whether they overlapped with a 
representative ligand. A consensus site that overlapped with multiple representative 
ligands was assigned to the allosteric site with which it had the greatest overlap. Overlap 
between a consensus site and representative ligand was found by using SciPy to calculate 
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the convex hull of the ligand and determining whether any consensus site atoms were 
located within the convex hull.  
 
2.4.4 Druggability assessment 
The strength of a consensus site (based on its population) can be considered as a 
measure of the potential binding affinity at that site. A kinase was considered druggable 
at a particular allosteric site if at least one of its structures had a strong consensus site (at 
least 16 probe clusters) assigned to that allosteric site. For a site to be druggable using 
conventional small molecule drugs, the positions of other nearby consensus sites would 
also need to be considered, but the main factor in determining whether a site would be an 
appropriate drug target is its potential to bind ligands with high affinity (Kozakov et al., 
2015b). Pockets with a slightly weaker consensus site (at least 13 probe clusters) would 
be considered borderline druggable, but an even weaker consensus site (less than 13 
probe clusters) would indicate that the site is not druggable at all.   
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CHAPTER THREE 
ClusPro-DC: Dimer Classification by the ClusPro Server for Protein-Protein 
Docking 
 
3.1 Introduction 
Many proteins function as assemblies of several polypeptide chains where 
homologous chains exhibit a high degree of symmetry. Over 80% of protein structures 
are determined by X-ray crystallography, and the arrangement of the subunits in an 
oligomeric protein often may not be reliably inferred from crystallographic studies. In 
fact, determining the quaternary structure and biological relevance of subunit interactions 
based on the X-ray structure alone is not straightforward (Janin, 1997; Valdar et al., 
2001). The contents of the asymmetric unit, which is the fraction of the crystallographic 
unit cell that has no crystallographic symmetry and is deposited in the Protein Data Bank 
(PDB), can describe one or several copies of a macromolecule without indicating the 
oligomeric state (e.g., monomer or dimer) that is most relevant in solution. Although 
crystallographic interfaces are generally smaller (less than 1000 Å2) than biologically 
relevant ones, there remains a substantial overlap between the distributions of the 
interface area for these two types of interactions. In addition, oligomerization depends on 
conditions such as concentration and pH and may be affected by truncation or mutation. 
Thus, experiments such as native gel electrophoresis, gel permeation chromatography, 
ultracentrifugation, or electrospray ionization time-of-flight mass spectrometry are 
needed to reliably establish the multimeric state of a protein (Fitzgerald et al., 1996). 
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Since experimental validation is often not available for a specific protein of 
interest, distinguishing biologically relevant interfaces from lattice contacts in protein 
crystals under native conditions has become a well-recognized problem in structural 
bioinformatics. A number of computational tools have been developed, with the methods 
belonging to two broad classes. The first class is based on estimating the stability of 
interaction based on the properties of the two proteins, using mostly, but not exclusively, 
the descriptors of the interface. One of the first methods published in this class was 
Protein Quaternary Structure (PQS), which used an empirical scoring function based on 
several contributions such as interface contact area, number of interfacial buried residues, 
salt bridges, disulfide bonds, and the solvation energy of quaternary structure formation 
(Henrick and Thornton, 1998). PQS has been developed into Proteins, Interfaces, 
Structures and Assemblies (PISA), which uses approximations of the enthalpic and 
entropic contributions to the binding free energy to predict the biological relevance of a 
macromolecular assembly (Krissinel and Henrick, 2007). The method considers buried 
surface area, hydrogen bonds, salt bridges, and disulfide bonds in order to estimate 
changes in enthalpy. For the entropic part, the translational, rotational, vibrational, and 
surface entropy components are estimated using subunit mass, surface area, symmetry 
number, and inertia moments. PISA has been implemented as a server that, in addition to 
determining the strength of the interactions, generates quaternary structure considering 
the symmetry mates. The server is very useful, and PISA has become the essential 
reference method, as it is currently used to predict quaternary structures of every entry in 
the PDB (Berman et al., 2000). A number of similar methods have been developed based 
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on various linear and nonlinear combinations of geometric and energetic descriptors of 
the protein–protein interface, in some cases involving machine learning and other 
statistical tools (Mitra and Pal, 2011; Bernauer et al., 2008; Tsuchiya et al., 2008; Luo et 
al., 2014; Da Silva et al., 2015). However, due to its importance, we still consider PISA 
to provide the “golden” standard for quaternary structure prediction. 
The second class of methods is distinguished by relying mainly on evolutionary 
information, although descriptors of the interface may also be included in the decision 
process (Valdar et al., 2001; Hou et al., 2015; Scharer et al., 2010; Duarte et al., 2012; 
Capitani et al., 2012). The most frequently used method in this class is Evolutionary 
Protein–Protein Interface Classifier (EPPIC) by Duarte et al. EPPIC uses a collection of 
classifiers based on evolutionary features and a simple geometric measure (Capitani et 
al., 2012). The evolutionary conservation of residues is assessed by constructing multiple 
sequence alignment of all sequence homologs to the target protein structure under study. 
For the geometric analysis, the interface core residues, defined as fully buried residues, 
provide fundamental determinants of biological interfaces: their number is in itself a 
powerful discriminator of interface character and helps the evolutionary measures to 
distinguish biological contacts from crystal ones. The evolutionary and geometric scores 
are combined to form a consensus call through a simple-majority voting scheme. EPPIC 
is also available as a server, which provides detailed information on all interfaces present 
in protein crystal structures in order to determine whether they are biologically relevant. 
Because the method used by EPPIC is substantially different from the method in PISA, 
and because of the availability of the server, we also consider EPPIC as a very important 
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contribution to quaternary structure prediction. 
In this paper, we introduce a straightforward method that, similarly to PISA, 
estimates the stability of the interaction between two protein subunits, but it is based on 
exhaustive sampling of the interaction energy landscape using a docking method rather 
than approximating the enthalpic and entropic contributions. The basic idea is extremely 
simple: we separate the two units of the dimer, consider one of the units and dock it to 
itself without any a priori assumption or restraint, evaluating the energy for billions of 
docked structures in the process. If a substantial number of low energy docked poses 
cluster in a narrow vicinity of the native structure, then we can assume that there is a 
well-defined free energy well around the native complex, which makes the interaction 
stable. In contrast, if the interaction sites in the docked structures do not form any cluster 
around the native state, then it is unlikely that the subunits form a stable biological dimer. 
As an illustration of this discrimination strategy, Figure 1a shows the docking of 
Escherichia coli met repressor (PDB ID 1cmb; solid surface in gray) to itself. The 100 
lowest energy poses (transparent cartoons in green) closely match the actual position of 
the second subunit, shown as a surface in green. Accordingly, the biological assembly as 
a homodimer was assigned by the authors (Rafferty et al., 1989) and supported by PISA. 
As the other extreme, Figure 1b shows docking results for soybean leghemoglobin A 
(PDB ID 1bin; gray surface), demonstrating a case where no low energy docked pose 
overlaps with the X-ray structure of the second subunit in the dimer (green surface). Such 
a result would be very unlikely for a protein that forms a dimer, and hence, we conclude 
that the C2 symmetry between the two subunits occurs only in the crystal. This prediction 
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is correct, since soybean leghemoglobin A is indeed a monomer in solution (Hargrove et 
al., 1997). 
 
Figure 3.1: Docking results for biological and crystallographic dimers. (a) Docking of E. 
coli met repressor (PDB ID 1cmb; solid surface in gray) to itself. The 100 lowest energy 
poses (transparent cartoons in green) closely match the actual position of the second 
subunit, shown as a surface in green. Met repressor is a homodimer in solution. (b) 
Docking of soybean leghemoglobin A (PDB ID 1bin, gray surface) to itself. No low 
energy docked pose overlaps with the X-ray structure of the second subunit in the dimer 
(green surface), indicating that there is no stable dimer in solution. Accordingly, soybean 
leghemoglobin A is a monomer. 
 
The advantage of the classifier presented here is that it is based on the well-
established docking method PIPER and its energy function as implemented in the 
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ClusPro 2.0 server (Kozakov et al., 2013). ClusPro has been very successful in all rounds 
of the Critical Assessment of Predicted Interactions (CAPRI) protein–protein docking 
challenge (Janin et al., 2013) and has thousands of regular users. Adding dimer 
discrimination to ClusPro required only two adjustable parameters, the radius of the near-
native region, defined in terms of RMSD from the X-ray structure of the dimer, and the 
number of docked structures that are expected to cluster in the near-native region in order 
to classify the dimer as biological rather than crystallographic. As will be shown, the 
need for only two parameters provides remarkable robustness to the method. 
Furthermore, we also estimate the probability of a dimer being biological, a continuous 
measure rather than only a yes-or-no decision. The classifier is freely available for 
academic and governmental use as part of the ClusPro server. We emphasize that at this 
point, the ClusPro-DC server is able to examine only the stability of an interface 
specified by the user rather than generating all putative quaternary structures as 
accomplished by both PISA or EPPIC. While we focus on methodology and describe a 
new prediction tool in this paper, our analysis also reveals that data on the quaternary 
structure of proteins are highly uncertain, and hence, comparing the performance of 
different methods using the available data has limited validity. 
 
3.2 Results and discussion 
 
3.2.1 Theoretical basis 
PIPER is a docking program that performs an exhaustive evaluation of simplified 
energy functions in discretized 6D space of mutual orientations of the protein partners. 
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The center of mass of the receptor is fixed at the origin of the coordinate system, and the 
possible orientational and translational positions of the ligand are evaluated at the given 
level of discretization. The rotational space is sampled at 70,000 rotations, which 
correspond to about 5 degrees step size in terms of the Euler angles. The translational 
space is represented as a grid of 1 Å displacement. It is easy to see that for an average 
size protein, this amounts to sampling 109–1010 conformations. In view of this global and 
systematic sampling on a dense grid, we can calculate an approximation of the overall 
partition function by Q = Σjexp(− Ej/RT), where Ej is the energy of the jth pose, and we 
sum over all poses. Similarly, we can approximate the partition function in a near-native 
region of the native complex by Qnn = Σjexp(− Ej/RT), where we sum over only the 
near-native poses (Kozakov et al., 2013). Based on these partition functions, the 
probability of the near-native state, Pnn, is Pnn = Qnn/Q. However, at this point, ClusPro 
routinely retains only the 1000 lowest energy docked structures. Fortunately, the 
dominant part of the partition function is provided by these 1000 structures, and hence, 
the probability of the near-native state is approximated by Pnn ≈ Q′nn/ Q′, where Q′ is the 
approximation of the partition function using the lowest energy 1000 structures. 
Similarly, Q′nn is the approximation of Qnn in a near-native region of the native complex 
but using only the near-native structures among the 1000 low energy ones retained. 
Furthermore, since the low energy structures are from an energy range that is very 
narrow, relative to the overall energy variation, and the energy values are calculated with 
considerable error that is comparable to the energy range considered, it is reasonable to 
assume that these energies do not differ, that is, Ej = E for all j. Although neglecting the 
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energy differences among the low energy structures seems to be arbitrary, we employ this 
approximation in our docking server ClusPro with success. Thus, the approximation 
seems to be adequate for proteins that are amenable to rigid-body docking, that is, those 
that are subject to only moderate conformational changes upon binding. This implies that 
Q = exp(− E/RT) × N and Qnn = exp(− E/RT) × Nnn, where N is 1000, and Nnn is 
the number of the low energy structures in the near-native region. Therefore, the 
probability of the near-native state is approximated by Pnn ≈ Nnn/1000, and thus, the 
probability of the ligand protein finding a stable near-native binding position on the 
receptor protein is proportional to the number Nnn of the near-native structures among the 
1000 retained. Accordingly, we will use Nnn for predicting the probability of forming a 
stable dimer that is independent of the crystal lattice and hence also occurs in solution. To 
obtain this predictor, we need to select only the radius that defines the appropriate 
neighborhood of the native state in terms of RMSD from the latter. To have a biological 
vs. crystallographic classifier comparable to PISA or EPPIC, we also select a threshold T 
on the number of structures in the near-native region such that Nnn ≤ T implies 
crystallographic, whereas Nnn > T means a biological dimer. As will be discussed, we also 
derive an interaction between Nnn and the probability P of a dimer that is considered 
biological, and we show that the selected threshold value T occurs at P = 0.5, which is 
thus used as the actual threshold. 
 
3.2.2 Training set selection and results 
For developing the method, we used a set of biological dimers (Bahadur et al., 
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2003) and a set of large interface crystal dimers (Bahadur et al., 2004), both manually 
selected from the PDB. The dimerization state of each protein in solution was checked 
with the biochemical literature, and it was also verified that the sequence of the 
crystallized fragment was the one used for multimeric studies. Indeed, experimental 
results show that the full-length protein forming a stable dimer cannot guarantee that a 
fragment will also form a stable dimer (Bernauer et al., 2008). Any dimer was rejected if 
more than 5% of the interface area was contributed by ligands, prosthetic groups, or other 
non-protein elements. The original set of homodimers contained 122 entries, but we have 
removed alpha-chymotrypsin (PDB ID 4cha) because it is not a homodimer (Tsukada and 
Blow, 1985), and glutathione reductase (PDB ID 3grs) because the PDB file lacked the 
symmetry information needed to generate a dimeric structure for docking. The PDB IDs 
of the remaining 120 structures are listed in Table 3.1. We note that this set includes most 
of the homodimers from the Ponstingl dataset (Ponstingl et al., 2003), frequently used for 
training and testing dimer discrimination methods. Some structures from the Ponstingl set 
were updated by Bahadur et al. to consider higher resolution structures. In addition, we 
replaced the structure of aldehyde oxidoreductase from Desulfovibrio gigas (PDB ID 
1alo) with a newer one (PDB ID 1vlb). As for the set of crystal dimers, we considered the 
103 structures with 2-fold symmetry that were selected by Bahadur et al. to have an 
interface area greater than 800 Å2. The PDB structure 1hfv of the G-protein ARF6 was 
superseded and thus replaced by PDB structure 2j5x. Some proteins in the Bahadur set 
had several interfaces that satisfied this condition, but we have retained only the largest 
interface per PDB entry, reducing the set to 89 entries (also listed in Table 3.1). As in the 
  
 
43 
case of the homodimers, many of these proteins were also in the Ponstingl dataset. 
However, the latter included structures with packing interfaces that buried less than 800 
Å2 and hence were not considered in our training set. 
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Table 3.1: Training set PDB entries 
A. Biological homodimers 
12as 1a3c 1a4i 1a4u 1aa7 1ad3 1ade 1af5 1afw 1ajs 
1alo 1amk 1aor 1aq6 1auo 1b3a 1b5e 1b67 1b8a 1b8j 
1bam 1bbh 1bd0 1bif 1biq 1bis 1bjw 1bkp 1bmd 1brw 
1bsl 1bsr 1buo 1bxg 1bxk 1cdc 1cg2 1chm 1cmb 1cnz 
1coz 1csh 1ctt 1cvu 1czj 1daa 1dor 1dpg 1dqs 1dxg 
1e98 1ebh 1f13 1fip 1fro 1gvp 1hhp 1hjr 1hss 1hxp 
1icw 1imb 1isa 1ivy 1jhg 1jsg 1kba 1kpf 1lyn 1m6p 
1mkb 1mor 1nox 1nse 1nsy 1oac 1opy 1pgt 1pre 1qfh 
1qhi 1qr2 1r2f 1reg 1rfb 1rpo 1ses 1slt 1smn 1smt 
1sox 1tc1 1tox 1trk 1uby 1utg 1vfr 1vok 1wtl 1xso 
2arc 2ccy 2hdh 2ilk 2lig 2mcg 2nac 2ohx 2spc 2sqc 
2tct 2tgi 3dap 3sdh 3ssi 4kbp 5csm 5rub 8prk 9wga 
B. Crystallographic dimers 
13pk 1a7v 1ad5 1afk 1ag9 1ah7 1ako 1amu 1atl 1aw7 
1ayl 1b1j 1b3j 1bc2 1bea 1bin 1bkz 1bs2 1byo 1c02 
1caq 1ck7 1cki 1clu 1cqx 1dsu 1dys 1e0s 1ehy 1epa 
1ewf 1feh 1fgk 1fjm 1fkd 1fmt 1g2a 1gar 1gjm 1hf8 
1hfv 1ilr 1kpt 1kwa 1mpg 1mss 1naw 1np4 1pbg 1pda 
1ppo 1qaz 1qci 1qdm 1qha 1qjp 1qme 1qpa 1qtq 1rb3 
1rhs 1rne 1shk 1the 1tht 1toa 1ton 1urp 1vbt 1xgs 
256b 256l 2acy 2atj 2bc2 2bls 2erc 2g3p 2ihl 2mbr 
2scp 2shp 2tps 2ugi 3mht 3pmg 5tss 830c 8pti  
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For each dimer, we used the PISA server to select the interface with the largest 
area for examination; symmetry mates were generated using PyMOL if the PDB file did 
not already contain the largest interface. In spite of considering crystal dimers with large 
interfaces, the average interface area was still substantially smaller than that of the 
biological dimers (863.7 Å2 vs. 1923.7 Å2, respectively). Although the standard 
deviations are large, based on the t-test, the difference is significant (p < 0.0001). 
However, the two distributions significantly overlap, as many biological dimers have 
interface areas below 1000 Å2 (see Figure 3.2a), and hence, discrimination on the basis of 
interface area alone is only moderately successful. We have used the ClusPro server with 
the standard PIPER energy function to dock the proteins to their own copies in both 
biological and crystallographic dimer sets and retained the 1000 lowest energy docked 
structures as usual in ClusPro (see Methods). Near-native structures were defined as 
having less than 7 Å2 Cα interface RMSD (IRMSD) from the X-ray structure of the 
complex (see Methods). As expected, biological dimers were found to have more near-
native docked poses than crystal dimers within the top 1000 structures. Figure 3.2b shows 
the fraction of biological dimers as a function of Nnn, the number of near-native 
structures. At low values of Nnn (< 30), this fraction is relatively small, but biological 
dimers become dominant for Nnn > 40 or so. Indeed, the average values of Nnn are 25.33 
and 129.40, respectively, for crystallographic and biological dimers. Although the data 
are noisy, smoothing the relationship provides a curve that, for any given Nnn, can be used 
to predict the probability of a dimer being biological. As mentioned, a classifier between 
crystallographic and biological dimers can be introduced by selecting a threshold value T 
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such that dimers with Nnn < T are predicted to be crystallographic, whereas with Nnn ≥ T 
are predicted to be biological. Figure 3.2c shows the receiver operating characteristic 
curve for the binary classifier above, as the value of Nnn is varied. Based on this curve, T 
= 33 appears to be a reasonable choice for the threshold between crystallographic and 
biological dimers. In good agreement with this selection, at Nnn = 33, the probability P of 
being a biological dimer is between 0.48 and 0.52, depending on the level of smoothing 
of the probability curve, and we select P = 0.5 as the probability threshold between 
crystallographic and biological dimers. We note that the Matthew correlation coefficient 
also reaches its maximum at Nnn = 33. Table 3.2 compares the results obtained by the 
docking-based approach using this threshold with the results of the two most established 
methods of dimer classification, PISA and EPPIC, from their server implementations. For 
biological multimers, all three methods work equally well, with over 90% success rate.  
PISA and EPPIC were found to disagree for 16 structures in the multimer set, and 
ClusPro provides the correct classification in 15 of these, which shows the motivation for 
using ClusPro as an additional method in case of uncertainty. As for the proteins with 
large crystallographic interfaces that are considered monomeric by Bahadur et al., both 
EPPIC and ClusPro predict close to 80% of these dimers as merely crystallographic, but 
according to PISA, more than 50% of these interactions are biological and stable (Table 
3.2). We originally believed that this is because PISA introduces the class of uncertain 
structures, in addition to biological multimers and dimers. According to the PISA server, 
the quaternary structure falls into a gray region of the complex formation criteria and may 
or may not be stable in solution for 14 proteins. Two of these uncertain predicted 
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structures are dimers, and the other 12 are putative monomers. However, even adding all 
uncertain structures as correctly predicted monomers, PISA would still predict fewer 
structures to be monomers than EPPIC or ClusPro would (55 vs. 68 and 71). According 
to Bahadur et al., the monomeric state of each protein in this set was first assessed from 
the BIOLOGICAL_UNIT record if present in the PDB entry and then checked against 
the PQS server and against the literature, and only entries for which the monomeric state 
could be confirmed by biochemical or biophysical data were retained. In spite of these 
assurances, in five cases, all three methods predict the multimers to be biological. Among 
these five, the author determined that the biological unit is monomeric for 1ehy and 830c, 
but dimeric for 1c02, 2scp, and 1mss. In addition, both ClusPro and PISA predict seven 
more structures as stable multimers, and the author's determination shows similar 
variation between monomeric and dimeric. Thus, we conclude that in spite of the analysis 
by Bahadur et al., the reliability of quaternary structure assignment is limited even in the 
heavily used classic dataset. However, further analysis of this problem is beyond the 
scope of this paper. Assuming that the assignments are correct, the overall success rate of 
quaternary structure prediction is 85.6% and 86.6%, respectively, for EPPIC and ClusPro, 
but only 72.7% for PISA, primarily due to the discussed overprediction of multimers. For 
the ClusPro-based method, the area-under-the-curve value based on Figure 3.2c is 0.89, 
which is comparable to the performance reported for the other two methods. 
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Figure 3.2: Selected results for training and “difficult” test sets. (a) Distributions of 
interface areas for biological dimers (green curve) and crystallographic dimers (red 
curve) in the training set. (b) Fraction of biological dimers as a function of Nnn, the 
number of low energy docked structures within 7 Å Cα IRMSD of the native structure. 
The direct data are shown as the bar graph, with the smoothed probability values as the 
continuous curve. The red vertical line shows the threshold value T = 33 for Nnn. (c) 
Receiver operating characteristic curve for the binary classifier as the value of Nnn is 
varied. Based on this curve, T = 33 appears to be a reasonable choice for the threshold 
Nnn value to discriminate between crystallographic and biological dimers. The area-
under-the-curve (AUC) value is 0.89. (d) Distributions of interface areas for biological 
dimers (green curve) and crystallographic dimers (red curve) in the “difficult” subset of 
the test set. 
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Table 3.2: Comparison the performance of the three servers 
Set Property PISA EPPIC ClusPro 
Training set 
Dimers: 120 Dimer correct 111 (92.5%) 111 (92.5%) 110 (91.7%) 
Monomers: 89 Monomer correct 41 (46.1%) 68 (76.4%) 71 (79.8%) 
Total: 209 Total correct 152 (72.7%) 179 (85.6%) 181 (86.6%) 
 Sensitivity & specificity 0.93 & 0.46 0.93 & 0.76 0.92 & 0.80 
 F1 value 0.8 0.88 0.89 
DC set 
DC Bio: 63 Dimer correct 42 (66.7%) 59 (93.7%) 58 (92.1%) 
DC Xtal: 78 Monomer correct 42 (53.8%) 51 (65.4%) 47 (60.3%) 
Total: 141 Total correct 84 (59.6%) 110 (78.0%) 105 (74.5%) 
 Sensitivity & specificity 0.67 & 0.54 0.94 & 0.65 0.92 & 0.60 
 F1 value 0.6 0.79 0.76 
Test set 
Dimers: 293 Dimer correct 208 (69.8%) 223 (74.8%) 223 (74.8%) 
Monomers: 
490 
Monomer correct 378 (77.1%) 385 (78.6%) 395 (80.6%) 
Total: 783 Total correct 586 (74.8%) 608 (77.7%) 618 (78.9%) 
 Sensitivity & specificity 0.71 & 0.77 0.76 & 0.79 0.76 & 0.81 
 F1 value 0.68 0.72 0.73 
“Difficult” subset 
Dimers: 56 Dimer correct 34 (60.7%) 15 (26.8%) 31 (55.4%) 
Monomers: 86 Monomer correct 31 (36.0%) 39 (45.3%) 55 (64.0%) 
Total: 142 Total correct 65 (45.8%) 54 (38.0%) 86 (60.6%) 
 Sensitivity & specificity 0.61 & 0.36 0.27 & 0.45 0.55 & 0.64 
 F1 value 0.47 0.25 0.53 
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3.2.3 Test set selection and results 
We tested the methods on three different sets of proteins. Table 3.2 compares the 
classification results by ClusPro, PISA, and EPPIC for all three sets. The first set, 
collected by Duarte et al., includes the DCxtal set of proteins with large crystal contacts 
(78 entries validated as monomers) and the DCbio set of proteins with small biological 
interfaces (63 validated as homodimers). For the entries in these sets, the oligomeric 
structure was experimentally verified, the crystal entries were checked to fulfill a series 
of quality criteria, and the focus was on the range of interface areas where it was really 
difficult to distinguish crystal from biological contacts. Indeed, the interface areas are 
similar, 1309.0 Å2 and 1212.5 Å2, respectively, for DCbio and DCxtal. Nevertheless, 
both EPPIC and ClusPro perform fairly well (78.0% and 74.5% overall success rates), 
whereas PISA is again biased toward multimers, resulting in a 59.6% overall success rate. 
For the second test set, we collected newly published structures from the PDB 
using the following criteria: (1) PDB release date between January 2014 and August 
2015; (2) no ligands in the structure; (3) only a single type of protein in the structure: that 
is, no heterodimers; and (4) the PDB file describes the author-determined biological 
assembly as suggested by the authors. The resulting set contains 783 entries, with 293 
biological multimers and 490 monomers. The interface areas differ substantially: 1635.0 
Å2 for biological but only 793.6 Å2 for the crystallographic multimers. However, the 
advantage of this set is that the proteins were not used to train PISA, EPPIC, or ClusPro. 
Table 3.2 compares the classification results by the three methods with the assignment of 
biological assembly provided by the authors in the PDB file. We are aware that the 
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biological assembly assigned by the authors is not necessarily correct and that in some 
cases, relevant publications may provide more valid classification. However, selecting 
publications for evaluating the three methods, even when some information is available, 
would introduce a substantial level of subjectivity, and thus we retained the author's 
assignment as the “true” state of quaternary assembly. According to Table 3.2, the three 
methods perform almost equally well, with PISA only slightly worse than the other two. 
For the third test set, we selected the “difficult” subset of the test set by adding a 
fifth selection criterion: (5) results from EPPIC and PISA conflict, as in one method 
considers the dimer biological and the other crystallographic, or the classification by 
PISA is uncertain. The “difficult” subset contained 142 entries total, with 56 biological 
multimers and 86 monomers. As shown in Figure 3.2d, for these two sets, the interface 
areas are small, and their distributions are almost identical. Although the average 
interface area of the biological multimers, 994.3 Å2, is slightly higher than that of the 
crystallographic ones, 934.1 Å2, a two-sided t-test shows that the difference is not 
significant (p > 0.1). Thus, this test set is different from the ones used earlier. As shown 
in Table 3.2, on the “difficult” set, all three methods perform much worse than on the 
training set and on the other two test sets, but now ClusPro is better than the other two. 
As in the other sets, PISA works relatively well for multimers, but it classifies 42 of the 
86 monomers as stable multimers, in addition to predicting 14 structures as uncertain 
multimers, resulting in the success rate of only 36.0% (Table 3.2). In contrast to its good 
performance on the training and Duarte-Capitani datasets (DC sets), EPPIC recognizes 
only 15 of the 56 multimers as biological (26.8% correct), primarily because many of the 
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more recently crystallized proteins have only a few homologs or no homolog at all, and 
hence, the evolutionary criteria could not be used. Consequently, both PISA and EPPIC 
have relatively low overall success rates, 45.8% and 38.0%, respectively. In contrast, the 
overall success rate for ClusPro is 60.6%. However, we note that selecting the “difficult” 
cases for which PISA and EPPIC contradict each other makes our analysis on this 
“difficult” subset biased against these two methods. Nevertheless, the application to this 
set of proteins is useful for demonstrating that ClusPro can be a valuable tool in 
improving the reliability of quaternary structure prediction when the results obtained by 
the standard methods are uncertain. 
Extending the analysis above, we applied the three methods to subsets of the test 
set from several interface area ranges. Predictions were separately analyzed for interface 
areas below 600, 800, and 1000 Å2. Results show that the identification of very small 
interface area biological dimers is difficult. For proteins with interface areas of less than 
600 Å2, the success rate was only 23.5% (4 out of the 17 cases) for all three methods. 
However, since the overall percentage of biological dimers with such small interface is 
low (17 out of 783, thus 2.17%), the overall success rate was over 90%, in spite of the 
inability to correctly identify most of the dimers.  
 
3.2.4 The ClusPro-DC server 
Dimer classification has been added as a new option to our protein–protein 
docking server ClusPro. The server can be used without a user account or with a user 
account (if one has an educational or governmental email address). Users with an account 
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can request an e-mail to be sent when any submitted job is completed. The server opens 
at the ClusPro home screen, and the user can select the option “Dimer Classification” 
rather than the option “Dock”. This opens the dimer classification page, where the user 
can provide a job name for the submission and then input the coordinates of a homo-
oligomer using the PDB format. There are two options for input: importing the 
coordinates from the PDB or uploading a structure. Only atoms of 20 standard amino 
acid residues are retained. The next step is selecting the two chains of the dimer that 
define the interface of interest. Multiple chains, separated by whitespace, can be selected 
in each box. Clicking the “Submit” button will start the calculation. The status of the job 
can be immediately checked from the “Queue” page. Clicking the job ID opens the status 
page, which shows the job ID, job name, user name, a status update, and pictorial 
representations of the uploaded and processed input structures. If requested, an email will 
be sent when the job has completed or if an error occurred. The email will contain a link 
to the results or error message. One can click the link or, alternatively, locate the results 
under the Results tab on the server, which shows the number Nnn of near-native docked 
structures among the 1000 lowest energy structures and the implied probability of the 
interaction being a biological dimer. One can also download a PyMOL session that shows 
the 100 lowest energy structures as transparent cartoons out of the 1000 retained. 
We demonstrate the application of the server to modulator protein MzrA (PDB ID 
4pwu), which was the target T70 of the CAPRI protein docking experiment (Janin et al., 
2003). In Round 30 of CAPRI, the challenge was to predict the structure of homo-
oligomers based on the sequence of the protein, before the release of the structure to the 
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PDB (Lensink et al., 2016). Since then, the coordinates of most targets, including T70, 
have been released. According to the author, 4pwu is a dimer, but according to PISA, it is 
a tetramer. The PDB for 4pwu provides four chains (A, B, C, and D), and we first 
analyzed the stability of A:B, C:D, and A:C interactions. The probability of the A:B 
dimer being biological was found to be 97%, and the same strong interaction exists for 
the C:D interface. For the A:C interaction, the probability of being stable is only 11%, but 
there is strong binding on the other side of the A subunit (Figure 3.3). In fact, PyMOL 
generates a symmetry mate at that position, and it is included in the A2:B2 tetramer 
constructed by PISA. Therefore, we tested the stability of the interaction between two 
A:B dimers and found it to be biological with 75% probability, implying that 4pwu forms 
a tetramer, in agreement with the PISA assessment. Note that although for 4pwu, we had 
four chains in the asymmetric unit, direct analysis of these subunits confirmed only a 
biological dimer, and it was necessary to generate the symmetry mates to determine all 
biological interfaces. Alternatively, one can generate and download the quaternary 
assemblies using PISA. At this point, the ClusPro-DC server is able to examine only the 
stability of an interface specified by the user, rather than generating all putative 
quaternary structures as accomplished by both PISA and EPPIC. Thus, we think that the 
primary application of the server is confirming the results obtained by PISA or EPPIC, 
particularly if the two contradict to each other. 
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Figure 3.3: Results of the analysis of the interaction between chains A and C in CAPRI 
target T70 (Modulator protein MzrA, PDB ID 4pwu). The docked poses show strong 
interactions on the other side of subunit A. PyMOL generates a symmetry mate at that 
position, and the ClusPro result indicates a biological interface in addition to the one in 
the A:B dimer. This results in the stable A2:B2 tetramer. 
 
 
3.3 Methods 
 
3.3.1 Selection of the test set and its “difficult” subset 
We selected the PDB files with release dates between January 2014 and August 
2015 with no ligands and with one type of protein only, resulting in 783 structures. To 
determine the assignment by PISA for each structure, we downloaded the xml for 
“macromolecular assemblies” and selected the most probable multimeric state, which 
was the first assembly listed in the xml. All potentially uncertain assignments were 
checked by manual submission to the PISA server. To determine the assignment by 
EPPIC for each structure, we downloaded the xml file. The multimer was considered 
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biological if any interface was assigned as “bio” in the consensus column. We identified 
142 structures with conflicting results from EPPIC and PISA, or with uncertain PISA 
assignment, and these structures were used as the “difficult” subset of the test set. 
 
3.3.2 Dimer classification by ClusPro 
ClusPro performs rigid-body docking using PIPER, a docking program based on 
the Fast Fourier Transform correlation approach. For generating putative dimeric 
structures, we consider the given protein structure as the receptor and a second copy of it 
as the ligand. The center of mass of the receptor is fixed at the origin of the coordinate 
system, and the possible orientational and translational positions of the ligand are 
evaluated on a dense grid, evaluating the energy for billions of poses. ClusPro retains the 
1000 lowest energy docked structures. We then determine the number Nnn of such 
structures with less than 7 Å Cα IRMSD from the native state. While other IRMSD values 
between 5 Å and 10 Å were also tested, 7 Å IRMSD provided the best discrimination 
between biological and crystallographic dimers in the training set. To calculate the 
IRMSD of a docked structure, we first select the interface residues in the X-ray structure, 
defined as the ligand residues that have any atom within 10 Å of any receptor atom. We 
then superimpose the receptors in the docked and X-ray structures and calculate the Cα 
RMSD for the selected interface residues. We determined the relationship between Nnn 
and the fraction of biological dimers in the training set (Figure 3.2b), and after 
smoothing, the relationship was used to estimate the probability of a specific structure 
being a biological dimer on the basis of the Nnn value obtained by the docking.  
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CHAPTER FOUR 
Prediction of Mutation-triggered Supramolecular Self-assembly Using ClusPro 
4.1 Introduction 
Proteins are frequently able to form supramolecular assemblies--large complexes 
of protein subunits that are bound together by noncovalent interactions--even though this 
ability also increases the risk that they will assemble into harmful aggregates, because 
these complexes are essential to many physiological processes (Gsponer et al., 2012). For 
example, metabolic enzymes have been found to organize into supramolecular assemblies 
upon nutrient deprivation; cells use these complexes as storage for enzymes when 
nutrients are scarce and the normal quantity of metabolic enzymes is unnecessary, and 
they allow cells to adapt quickly if conditions change, as these complexes dissociate 
readily when nutrients are once again available (Narayanaswamy et al., 2009). This 
process can occur on a regular basis--such as in maize, where hexamers of adenylate 
kinase are stacked linearly into rods each night upon the suspension of carbon dioxide 
assimilation, but each morning AMP levels rise and cause the rods to disassemble (Wild 
et al., 1997) — or in cases of extreme starvation, which has been found to occur in yeast 
with glutamine synthetase (Petrovska et al., 2014).  In addition to acting as storage for 
inactive enzymes, supramolecular assemblies are involved in many cellular signaling 
processes, such as signal amplification, compartmentalization of biochemical reactions, 
and reduction of biological noise (Wu, 2013). The formation of supramolecular 
assemblies can thus be critical to cell function in both normal and extreme conditions. 
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Figure 4.1: Structure of adenylate kinase hexamer in maize (top); adenylate kinase 
hexamers assembled linearly into rod-like structure (bottom).  
 
Supramolecular self-assembly can be triggered by changes in the environment, 
such as nutrient availability, pH, temperature, or by mutated residues (Noree et al., 2010). 
In a recent publication, Garcia-Seisdedos et al. found that introducing a single point 
mutation could cause Escherichia coli homomers with dihedral symmetry to assemble 
into protein fibers or punctate foci (Garcia-Seisdedos et al., 2017). Unlike the forms of 
aggregation that are often associated with human diseases—such as amyloid fibrils, 
which have been linked to Alzheimer’s and Parkinson’s disease—these complexes did 
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not unfold before assembling into fibers or foci, and their association could easily be 
reversed by lowering the ionic strength. These properties indicated that the homomers 
had formed structures that were more consistent with the supramolecular assemblies 
described earlier, rather than harmful aggregates. The Escherichia coli complexes ranged 
in size from having six to ten subunits, with most having either eight or ten, that were 
arranged as two rings stacked on top of each other. To promote supramolecular self-
assembly, Garcia-Seisdedos et al. mutated residues located at the head of each ring, 
which would allow new head-to-head interactions to occur; as the complexes are 
symmetric, this would allow them to continue stacking indefinitely, into long fibers. 
Residues with low interaction propensity (K/E/D) were mutated to hydrophobic residues 
(Y/ L), which encouraged binding not only through the hydrophobic effect, but also by 
replacing residues that would discourage binding.  
We decided to see if this experiment could be replicated computationally using 
ClusPro, our protein-protein docking server. Since docking predicts likely poses for 
proteins to interact with each other, it should also be able to predict whether a mutation 
on the surface of a protein will likely trigger it to self-assemble, since such a mutation 
should then appear in the interfaces of the docked conformations more often. This is 
especially true for the supramolecular assemblies described by Garcia-Seisdedos et al., 
since the proteins were found to maintain their natively folded structures, and ClusPro 
performs docking with the rigid-body assumption, which assumes that conformational 
changes upon binding are moderate at most. To determine whether a mutation is likely to 
induce assembly, both mutated and wild type structures can be docked to themselves to 
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find the likely interactions, and the number of times the mutated residues appear in the 
predicted interfaces can be compared. If a residue appears significantly more often in the 
interfaces of the docked mutated structures, relative to the docked wild type structures, 
then it may be likely to cause self-assembly; otherwise, it is not likely to have an effect 
on whether supramolecular assemblies form. The ability to predict whether a mutation 
will trigger protein self-assembly would be useful in the design of biomaterials, such as 
nanotubes, cages, or lattices, and could have applications in studying diseases caused by 
mutations, although this method would be less appropriate if severe protein misfolding is 
involved. 
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Figure 4.2: Comparison of docking results for E. coli ketopantoate 
hydroxymethyltransferase (PDB ID: 1m3u) in which mutation(s) trigger supramolecular 
self-assembly (right: D157Y-E158Y-D161Y) or do not (left: D158Y). Ketopantoate 
hydroxymethyltransferase is a decamer, with two pentameric “rings”. The rings used for 
docking are shown as gray and green surfaces; docked structures (ten are shown here) are 
represented as transparent green cartoons. Mutated residues have been colored red. The 
results for D158Y show that the docked structures closely match the original two-ring 
structure, whereas for D157Y-E158Y-D161Y, some of the docked structures are now 
located on the other side of the ring, indicating new interactions driven by contacts 
between the mutated residues. These interactions would allow ketopantoate 
hydroxymethyltransferase to continue self-assembly into a structure of indefinite length 
(Garcia-Seisdedos et al. stated that this mutant formed protein fibers). 
 
 
4.2 Results 
Out of the 12 Escherichia coli complexes described by Garcia-Seisdedos et al., 
we predicted whether a set of mutations would lead to fiber or foci formation for 11; one 
complex (PDB ID 1d7a) was not included because its sequence did not match its listed 
mutations, which resulted in 67 mutants total, rather than the 73 created in Garcia-
Seisdedos et al. Fluorescence was used in the original experiment to observe whether 
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mutated homomers formed nuclei, foci, fibers, or remained homogeneous (did not self-
assemble), but docking was only used to predict whether assembly would occur, rather 
than what type. Results are given for each mutant in Table 4.1, with incorrect predictions 
for mutants that form assemblies shown in blue, and incorrect predictions for mutants that 
do not assemble shown in yellow; a summary of the results is given in Table 4.2. ClusPro 
was found to be more accurate for mutants that did form assemblies; it slightly 
overpredicted assembly formation for those that did not. 
 
Table 4.1: Assembly formation predictions for each mutant 
PDB ID Mutations Assembly Prediction 
1frw D170L-D173L-K175L-D176L foci assembly 
1frw D170L homogeneous assembly 
1frw D170Y-D173Y-K175Y-D176Y foci assembly 
1frw D173L homogeneous assembly 
1frw K175L homogeneous no change 
1frw D176L homogeneous no change 
1frw E129L-D131L foci no change 
1frw K118L-D119L-E129L-D131L foci no change 
1frw K118Y-D119Y-E129Y-D131Y foci assembly 
1l6w K97Y-K100Y-E102Y foci assembly 
1m3u D157L-E158L-D161L fibers assembly 
1m3u D157L-E158L homogeneous no change 
1m3u D157L homogeneous no change 
1m3u D157Y-E158Y-D161Y fibers assembly 
1m3u D157Y homogeneous no change 
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1m3u D161L homogeneous no change 
1m3u D161Y homogeneous no change 
1m3u E158L homogeneous no change 
1m3u E158Y homogeneous no change 
1pok E239L-E243L-K247L fibers assembly 
1pok E239L homogeneous no change 
1pok E239Y-E243Y-K247Y fibers assembly 
1pok E239Y fibers assembly 
1pok E243L homogeneous no change 
1pok E243Y homogeneous assembly 
1pok K206L-K207L-D214L-E217L nuclear assembly 
1pok K247L homogeneous no change 
1pok K247Y homogeneous no change 
1yac D92L-E94L-K98L-K101L foci assembly 
1yac D92Y-E94Y-K98Y-K101Y foci assembly 
2an9 D60Y-E61Y-K63Y-E64Y foci assembly 
2cg4 D131L homogeneous assembly 
2cg4 D131Y homogeneous assembly 
2cg4 K126L-D131L homogeneous no change 
2cg4 K126L homogeneous no change 
2cg4 K126Y-D131Y fibers assembly 
2cg4 K126Y homogeneous no change 
2cg4 K77L-K80L nuclear assembly 
2cg4 K77Y-K80Y-K88Y nuclear assembly 
2iv1 D66Y-D68Y-E69Y foci assembly 
2iv1 K24L-K25L-D26L foci no change 
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2iv1 K24Y-K25Y-D26Y foci assembly 
2iv1 K64L-D66L-D68L-E69L-D70L foci assembly 
2iv1 K64Y-D66Y-D68Y-E69Y-D70Y foci assembly 
2vyc D494L homogeneous no change 
2vyc D494Y homogeneous assembly 
2vyc D497L fibers no change 
2vyc D497Y homogeneous assembly 
2vyc E64L-D67L homogeneous assembly 
2vyc E64Y-D67Y nuclear assembly 
2vyc K491L-D494L-D497L fibers assembly 
2vyc K491L homogeneous no change 
2vyc K491Y-D494Y-D497Y fibers assembly 
2vyc K491Y fibers assembly 
2wcv E112L homogeneous assembly 
2wcv E112Y homogeneous assembly 
2wcv E77L homogeneous no change 
2wcv E77Y-E112Y homogeneous assembly 
2wcv E77Y fibers assembly 
3n75 D457L-D460L-D470L fibers assembly 
3n75 D457Y-D460Y-D470Y foci assembly 
3n75 D460L fibers no change 
3n75 D470L homogeneous no change 
3n75 K437L-K440L-E445L homogeneous no change 
3n75 K437Y-K440Y-E445Y-D457Y-D460Y-D470Y foci assembly 
3n75 K437Y-K440Y-E445Y-D470Y homogeneous assembly 
3n75 K437Y-K440Y-E445Y homogeneous assembly 
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Table 4.2: Summary of correct predictions 
Number Correct (Forms Assembly) 28 (84.8%) 
Number Correct (No Change) 21 (61.7%) 
Total Correct 49 (73.1%) 
F1 Score 0.76 
 
 
4.3 Discussion 
ClusPro offers a straightforward approach to predicting whether a set of mutations 
will induce protein self-assembly. Instead of considering the hydrophobicity of the wild-
type and mutated residues, or the number or interface area of the mutations, it simply 
looks at whether the mutated residues are more likely to be present in the interfaces of 
potential assemblies. This likely contributes to its success in determining whether the 
mutated homomers formed assemblies, as the number of point mutations made did not 
necessarily correspond to the likelihood of assembly formation; in some cases, one point 
mutation was sufficient for foci or fibers to form (1pok E239Y), whereas multiple 
mutations to hydrophobic residues did not necessarily trigger self-assembly (3n75 
K437L-K440L-E445L). 
 
4.3.1 Application in design of biomaterials 
Rather than using screening to select residues for mutation that would likely lead 
to new interactions, Garcia-Seisdedos et al. chose to create mutants with only a few 
mutations at most (up to six per protein), on the basis of where the residues were located. 
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Such minor changes, which were sufficient to induce fiber or foci formation in many of 
the mutants, should frequently be sampled by evolution; many other protein complexes 
are likely to have this property as well. This ability to form supramolecular assemblies 
can be exploited to design novel self-assembling biomaterials, such as cages, layers, and 
filaments, and ClusPro could be used to determine which mutations would lead to self-
assembly. 
 
4.4 Methods 
 
4.4.1 Preparation for docking 
Each of the 11 homomers was downloaded from the Protein Data Bank (PDB) 
and split in half into rings by visual inspection. SCWRL4 was used to introduce 
mutations into the structures without affecting the backbone conformation (Krivov et al., 
2009), since the homomers are known to remain in their natively folded state upon 
assembly; a different mutated structure was generated for each set of mutations.  
 
4.4.2 Docking to predict mutation-triggered assembly formation 
The wild-type and mutated structures were then docked using PIPER, and the 
70,000 lowest energy docked structures were retained for the next step. For each mutant, 
the number of times each of its mutated residues appeared in the interface was recorded, 
as well as how frequently those residues were observed in the interfaces of the docked 
wild-type structures. The sum of these residue appearances in the interfaces of the docked 
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mutated structures was then compared to that of the wild-type structures; for mutants that 
were observed to form assemblies, this ratio was expected to be significantly greater than 
1. A ratio of 1.7 mutant to wild-type residue counts was found to be an appropriate cutoff 
for determining whether a set of mutations would trigger supramolecular self-assembly. 
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